Mirum Pharmaceuticals (Mirum Pharmaceuticals) Debt-to-Equity : 1.24 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mirum Pharmaceuticals Debt-to-Equity?

Mirum Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.1 Mil. Mirum Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $307.0 Mil. Mirum Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $248.7 Mil. Mirum Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 1.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mirum Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

MIRM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 1.24
Current: 1.24

During the past 6 years, the highest Debt-to-Equity Ratio of Mirum Pharmaceuticals was 1.24. The lowest was 0.02. And the median was 0.02.

MIRM's Debt-to-Equity is ranked worse than
90.37% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs MIRM: 1.24

Mirum Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Mirum Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Debt-to-Equity Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

1.24

Mirum Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.01	3.92	1.15	1.24

Competitive Comparison of Mirum Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Mirum Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Debt-to-Equity falls into.

Mirum Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mirum Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.104	+	307.038)	/	248.67
	=	1.24

Mirum Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.104	+	307.038)	/	248.67
	=	1.24

Mirum Pharmaceuticals (NAS:MIRM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mirum Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (NAS:MIRM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MIRM:Mexico 08D:Germany

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Executives

Peter Radovich	officer: Chief Operating Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jolanda Howe	officer: SVP, Global Controller	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Lara Longpre	officer: Chief Development Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Pamela Vig	officer: Chief Scientific Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Christopher Peetz	director, officer: President and CEO	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Patrick J Heron	director, 10 percent owner	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Michael G Grey	director, officer: Executive Chairman	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Lon Cardon	director	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Ian Clements	officer: SVP Finance & Communications	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404